# Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease

Study · id `cardio:ct-nct05196347` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05196347](<https://clinicaltrials.gov/study/NCT05196347>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05196347

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT05196347. Randomized; no masking; primary purpose treatment. Start 2022-05-27 (actual); primary completion 2024-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT05196347, source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)
- Started: 2022-05-27 (actual) (ClinicalTrials.gov record NCT05196347, source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)
- Primary completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT05196347, source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)
- Completion: 2024-08-31 (actual) (ClinicalTrials.gov record NCT05196347, source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT05196347, source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05196347-2025-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
- Acronym: DAPA-advKD
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Kaohsiung Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: d2498248c8735ba15cc92ec1ed32a3d0c73e6813758a05fb1f29b9802be16469
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
